Requirement of Bardet-Biedl syndrome proteins for leptin receptor signaling by Seo, Seongjin et al.
Requirement of Bardet-Biedl syndrome proteins
for leptin receptor signaling
Seongjin Seo1,3, Deng-Fu Guo2, Kevin Bugge1,3, Donald A. Morgan2, Kamal Rahmouni2, 
and Val C. Shefﬁeld1,3
1Department of Pediatrics,
2Department of Internal Medicine, University of Iowa Carver College of Medicine,
3135C MERF, Iowa, IA 52242, USA and
3Howard Hughes Medical Institute, Chevy-Chase, MD, USA
Received November 11, 2008; Revised and Accepted January 14, 2009
Obesity is a major public health problem in most developed countries and a major risk factor for diabetes and
cardiovascular disease. Emerging evidence indicates that ciliary dysfunction can contribute to human obes-
ity but the underlying molecular and cellular mechanisms are unknown. Bardet-Biedl syndrome (BBS) is a
genetically heterogeneous human obesity syndrome associated with ciliary dysfunction. BBS proteins are
thought to play a role in cilia function and intracellular protein/vesicle trafﬁcking. Here, we show that BBS
proteins are required for leptin receptor (LepR) signaling in the hypothalamus. We found that Bbs2
2/2,
Bbs4
2/2 and Bbs6
2/2 mice are resistant to the action of leptin to reduce body weight and food intake regard-
less of serum leptin levels and obesity. In addition, activation of hypothalamic STAT3 by leptin is signiﬁcantly
decreased in Bbs2
2/2, Bbs4
2/2 and Bbs6
2/2 mice. In contrast, downstream melanocortin receptor signaling
is unaffected, indicating that LepR signaling is speciﬁcally impaired in Bbs2
2/2, Bbs4
2/2 and Bbs6
2/2 mice.
Impaired LepR signaling in BBS mice was associated with decreased Pomc gene expression. Furthermore,
we found that BBS1 protein physically interacts with the LepR and that loss of BBS proteins perturbs
LepR trafﬁcking. Our data indicate that BBS proteins mediate LepR trafﬁcking and that impaired LepR
signaling underlies energy imbalance in BBS. These ﬁndings represent a novel mechanism for leptin
resistance and obesity.
INTRODUCTION
The increasing prevalence of obesity and its association with
various human disorders, such as diabetes and hypertension
has made studying the mechanisms that control energy homeo-
stasis a high priority. The environmental and genetic factors
contributing to the obesity ‘epidemic’ are currently under
intense investigation but our understanding of the molecular,
cellular and physiological processes that regulate energy
homeostasis and the defects leading to energy imbalance and
obesity is still far from complete. In mammals, body weight
and energy homeostasis are controlled by the interplay
between the peripheral signals and the brain, particularly the
hypothalamus (1). Leptin is an adipocyte-derived hormone
that circulates in proportion to the amount of body fat in
order to inform the brain about the peripheral fat storage
(2,3). Within the arcuate nucleus of the hypothalamus, a
major site for leptin action, leptin is known to act on at least
two neuronal populations: proopiomelanocortin (POMC)
neurons, which are activated by leptin and neuropeptide Y
(NPY) neurons [co-expressing agouti-related protein
(AgRP)] and are inhibited by leptin (1–4). In rodents and
humans, mutations in genes encoding leptin and the leptin
receptor lead to severe obesity, infertility and endocrine
dysfunctions (2,5).
Recent discoveries indicate that ciliary dysfunction is
associated with human obesity. Bardet-Biedl syndrome
(BBS) is the prototypical human genetic disorder associated
with ciliary dysfunction and obesity (6,7). To date, more
than 12 BBS genes have been identiﬁed and mutations in
BBS genes are associated with obesity, polydactyly and
retinal degeneration (6–8). Additional clinical features of
BBS include diabetes, hypertension, cognitive impairment,
renal anomalies and hypogenitalism (6–8). Although BBS
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trafﬁcking (6,9,10), the precise molecular function of each
BBS protein has not been characterized. Likewise, the patho-
physiological mechanisms leading to each component of the
BBS phenotype are unknown.
Previously, we demonstrated that obesity in BBS mice is
associated with hyperleptinemia and leptin resistance (11).
However, since leptin production is proportional to the
amount of body fat and, hyperleptinemia and leptin resistance
are frequently associated with obesity in animal models and
humans (3,12–14), leptin resistance in BBS mice could be
secondary to obesity, as opposed to being the cause of
obesity. Here, we addressed this question and uncovered the
molecular defects leading to energy imbalance in BBS. Using
a BBS knockout mouse model (Bbs2
2/2) (15), which recapitu-
late the major components of the human phenotype including
obesity, we demonstrate that BBS proteins are required for
LepR signaling. We conﬁrmed this with additional BBS
knockout mouse models (Bbs4
2/2 and Bbs6
2/2) (16,17). We
also demonstrate that BBS proteins physically interact with
the LepR and mediate LepR trafﬁcking. Our ﬁndings indicate
that attenuated LepR signaling owing to altered trafﬁcking of
the LepR is the major cause of obesity in BBS.
RESULTS
Bardet-Biedl syndrome mice have defects in the
hypothalamic leptin–melanocortin axis
To test whether the leptin resistance in BBS mice is secondary
to obesity, we examined the appetite-suppressing and
weight-reducing effects of exogenous mouse leptin in BBS
mice that had their circulating leptin levels normalized by
calorie restriction. Bbs2
2/2, Bbs4
2/2 and Bbs6
2/2 mice
were given 70–80% of the chow pellets normally consumed
daily by sex- and age-matched wild-type mice. This
calorie-restriction protocol effectively prevented obesity and
reduced serum leptin levels in BBS mice (Fig. 1A). While
Bbs2
2/2, Bbs4
2/2 and Bbs6
2/2 mice fed ad libitum showed
4–10-fold higher serum leptin levels [Fig. 1A and (11)], the
leptin levels of calorie-restricted Bbs2
2/2, Bbs4
2/2 and
Bbs6
2/2 mice were comparable with wild-type animals. Intra-
cerebroventricular (ICV) administration of leptin caused a
signiﬁcant reduction in food intake and body weight in wild-
type mice. In contrast, ICV leptin failed to reduce food intake
and body weight in Bbs2
2/2, Bbs4
2/2 and Bbs6
2/2 mice
despite the normal serum leptin levels (Fig. 1B and C). Food
intake adjusted to body weight yielded similar results (data
not shown). These results indicate that leptin resistance in
BBS mice is not secondary to obesity. Rather, these results
suggest leptin resistance as the cause of obesity in BBS mice.
Melanocortin receptors, which are downstream to LepR sig-
naling, are an important node for energy homeostasis (1,4).
Therefore,weexaminedwhethertheabilityofthemelanocortin
receptors to alter metabolism is also impaired in BBS mice. For
this, we tested the effect of ICV administration of melanotan II
(MTII), a melanocortin receptor agonist, on body weight and
food intake (Fig. 2A and B). In contrast to leptin, ICV MTII
reduced food intake and body weight in both wild-type and
Bbs2
2/2 and Bbs6
2/2 mice. In addition, MTII administration
reduced brown and white adipose tissues in both control and
BBS animals (Fig. 2C and D). These data indicate that the
ability of the melanocortin receptors to inﬂuence metabolism
is intact in BBS mice. Quantitative reverse-transcriptase poly-
merase chain reaction (qRT-PCR) results also demonstrated
that the expression of melanocortin-3 and -4 receptors was
normal in BBS mice (Supplementary Material, Fig. S1). Com-
bined, these data indicate that obesity in BBS animals is owing
to defect(s) downstream or at the level of LepR but upstream of
melanocortin receptors in the hypothalamic leptin–
melanocortin axis.
Attenuated leptin receptor signaling in Bardet-Biedl
syndrome animals
To determine the speciﬁc defect leading to leptin resistance in
BBS mice, we examined the expression and signaling capa-
bility of the long isoform of the leptin receptor (LepRb), the
isoform that has signaling capacity within the hypothalamus
(18,19). The mRNA levels of LepRb were not altered in
Bbs2
2/2, Bbs4
2/2 and Bbs6
2/2 mice compared with wild-
type controls (Fig. 3A). To examine whether the signaling
capacity of the LepRb is normal in BBS mice, we compared
the ability of leptin to activate hypothalamic signal transducer
and activator of transcription-3 (STAT3) between wild-type
and BBS mice. As above, leptin levels in BBS mice were
Figure 1. Bardet-Biedl syndrome mice are resistant to leptin. (A) Serum leptin levels of wild-type and calorie-restricted (CR) Bbs2
2/2 (2KO), Bbs4
2/2 (4KO)
and Bbs6
2/2 (6KO) mice. Serum leptin level of normally fed Bbs2 null mice was shown for comparison (n ¼ 4–16). (B, C) Bbs2, Bbs4 and Bbs6 null mice with
normal circulating leptin levels are still resistant to the weight- and appetite-reducing action of leptin. Changes in body weight and food intake were measured
24 h after ICV leptin administration (n ¼ 5–16). Data are mean + SEM.  P , 0.05 compared with wild-type mice;
†P , 0.05 versus vehicle.
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ondary to obesity. In control mice, leptin caused a robust
increase in STAT3 phosphorylation (Fig. 3B). However,
leptin-induced STAT3 phosphorylation was greatly reduced
in Bbs2
2/2, Bbs4
2/2 and Bbs6
2/2 mice (to 17–39% of the
control) albeit normal serum leptin levels in those mice
(Fig. 3B and C). These data demonstrate that leptin resistance
in BBS mice is caused by inability of the LepR to activate the
Figure 2. Bardet-Biedl syndrome mice are responsive to melanocortin receptor agonist, MTII. (A–D) BBS mice are responsive to the weight-, appetite- and fat
mass-reducing effect of MTII. Wild-type, Bbs2
2/2 and Bbs6
2/2 mice were injected with MTII or vehicle, and changes in body weight and food intake were
measured 24 h later. Brown adipose tissue and reproductive fat were measured after death in vehicle- or MTII-injected mice (n ¼ 4–7). Data are mean+SEM.
 P , 0.05 compared with wild-type mice; †P , 0.05 versus vehicle.
Figure 3. Impaired LepRb signaling in Bardet-Biedl syndrome (BBS) mice. (A) Expression levels of the long form LepR (LepRb). Relative amounts of LepRb
mRNAs were measured by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) after normalization with RPL19. Expression levels in wild-
type were arbitrarily set at 1 (n ¼ 6–9). (B) STAT3 phosphorylation upon leptin administration was reduced in BBS mice. BBS mice were calorie-restricted as
above to normalize serum leptin levels and injected with leptin. Hypothalamic protein extracts were analyzed by standard sodium dodecyl sulfate–
polyacrylamide gel electrophoresis and western blotting. (C) Quantiﬁcation of phosphorylated STAT3 from data used in (B). (D) Socs-3 mRNA level was
decreased in BBS mice. Socs-3 mRNA level was determined by qRT-PCR as above (n ¼ 4–8). (E) Protein levels of Socs-3, Syntaxin1 and Synaptophysin.
b-catenin was used as a loading control. Data are mean+s.e.m.  P , 0.05 compared with wild-type mice.
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receptor. In diet-induced obese mice, leptin resistance is
thought to be owing to an increase in suppressor of cytokine
signaling-3 (Socs-3), one of the targets induced by STAT3
and a negative feedback inhibitor of the LepR signaling
(20,21). We found that both mRNA (Fig. 3D) and protein
(Fig. 3E) levels of Socs-3 were decreased in Bbs2
2/2,
Bbs4
2/2 and Bbs6
2/2 animals, indicating that leptin resist-
ance in BBS mice was not because of increased expression
of Socs-3 in contrast to what is observed in diet-induced
obesity model. The potential role of other mechanisms such
as protein–tyrosine phosphatase 1B and the cyclic AMP
responsive element-binding protein-1 (Creb1)-regulated
transcription coactivator-1 in the leptin resistance associated
with BBS remains to be determined (22,23). We also found
that Bbs2
2/2, Bbs4
2/2 and Bbs6
2/2 mice had normal
expression of Syntaxin 1 (Fig. 3E), which was previously
shown to be downregulated in mice deﬁcient in leptin
(ob/ob) or LepRb (db/db) (24). Synaptophysin is a pan-
neuronal marker and its level was not changed in Bbs2
2/2,
Bbs4
2/2 and Bbs6
2/2 mice, indicating that there was no
gross loss of neurons in BBS mice (Fig. 3E). In summary,
our data indicate that leptin resistance in BBS mice is
because of attenuated LepR signaling in the hypothalamus.
Defective proopiomelanocortin neurons in Bardet-Biedl
syndrome animals
To gain further insight into the molecular and cellular mech-
anisms of obesity in BBS animals, we examined the
expression levels of key hypothalamic genes involved in
leptin action. Consistent with our previous ﬁndings (11), the
expression levels of the orexigenic Agrp and Npy genes
were normal, whereas the expression level of the anorexigenic
Pomc gene was signiﬁcantly lower in Bbs2
2/2, Bbs4
2/2 and
Bbs6
2/2 mice compared with wild-type controls (Fig. 4A).
Next, we tested whether the hypothalamic orexigenic and
anorexigenic genes responded properly to variations in the
peripheral energy balance in BBS mice by comparing the
mRNA levels of these neuropeptides in normally fed and
48 h fasted animals. In wild-type mice, AgRP and NPY
mRNA levels increased and POMC mRNA levels decreased
after fasting (Fig. 4B). In Bbs2
2/2 and Bbs4
2/2 mice,
changes in AgRP and NPY mRNA levels in response to
fasting were similar to that of wild-type controls. In contrast,
fasting-induced decrease in POMC mRNA levels was signiﬁ-
cantly less in Bbs2
2/2 and Bbs4
2/2 mice when compared
with wild-type controls (Fig. 4B). These data indicate that
POMC neurons of BBS mice do not respond properly to
changes in peripheral energy balance. Thus, POMC neurons
appear to be selectively affected in BBS mice downstream
of LepR signaling.
To test whether a reduction in the number of POMC
neurons may be the main defect in BBS mice, we compared
the number of these neurons in the hypothalamic arcuate
nucleus between wild-type and BBS mice. Immunohistochem-
istry results revealed that there was a slight reduction (approxi-
mately 20%) in POMC-positive cells in Bbs2
2/2 and
Bbs6
2/2 animals (Fig. 4C and D). However, this reduction
in POMC neurons cannot explain the approximately 40%
reduction in Pomc gene expression or the more than 60%
decrease in STAT3 phosphorylation. In addition, immuno-
staining of POMC in BBS animals was often weak (which is
consistent with the lower levels of POMC mRNA) suggesting
that the number of POMC neurons might be underestimated in
BBS mice. Combined with our biochemistry and gene
expression data, these results indicate that leptin resistance
in BBS mice is mostly because of attenuated LepR signaling.
Bardet-Biedl syndrome proteins interact with LepRb and
mediate LepRb trafﬁcking
Recently, it was found that seven BBS proteins (BBS1, BBS2,
BBS4, BBS5, BBS7, BBS8 and BBS9) form a stable complex
known as the BBSome (9). This complex is proposed as the
functional unit that mediates protein/vesicle trafﬁcking to
cilia. We postulated that some of the BBSome subunits
might interact with the LepRb and/or STAT3 to mediate
their trafﬁcking. Strikingly, we found that BBS1 protein
speciﬁcally interacted with the LepRb in transient transfection
and co-immunoprecipitation assays (Fig. 5A). No other
BBSome subunits showed interaction with LepRb. In addition,
the interaction between BBS1 and LepR was speciﬁc to the
signaling isoform of the receptor, LepRb, because the non-
signaling isoform, LepRa, did not interact with BBS1
(Fig. 5B). Consistent with this, we found that the C-terminal
cytoplasmic domain of LepRb, which is unique to the
LepRb, was sufﬁcient to interact with BBS1 (Fig. 5C). We
did not detect any interaction between STAT3 and BBS pro-
teins (data not shown). The BBS1 M390R mutation, which
is the most common mutation found in human BBS patients
and sufﬁcient to induce BBS phenotypes including obesity
in a knock-in mouse model (25), greatly reduced the ability
of BBS1 to interact with the LepRb (Fig. 5D). The BBS1
M390R mutant also showed decreased interaction with the
LepRb cytoplasmic domain (Fig. 5C). To test whether the
interaction between BBS1 and LepRb occurs in living cells,
we transfected ARPE-19 cells with BBS1 either alone or
with the LepRb. We found that although overexpressed
BBS1 proteins were detected throughout the cytoplasm,
co-transfection of LepRb with BBS1-restricted BBS1 localiz-
ation to small punctuates in ARPE-19 cells (Supplementary
Material, Fig. S2), supporting the physical interaction of
LepR with BBS1. Altogether, these ﬁndings indicate that
LepRb can be associated with the BBS1 subunit of the
BBSome.
Finally, we tested whether LepRb trafﬁcking was altered in
the absence of BBSome proteins. Consistent with previous
studies of the localization of the LepR (26,27), most LepRb
immunoreactivity was found in the trans-Golgi network
(TGN) and small vesicles, and only a very low level of the
LepRb was detected in the plasma membrane (Fig. 6A and
Supplementary Material, Fig. S3). Some of the small vesicles
showing immunoreactivity for LepRb were positive for
TGN46, a marker for post-Golgi vesicles as well as TGN
(28), suggesting that these vesicles are in the secretory
pathway or recycling endosomes. A fraction of the LepRb
was also found in the early endosomes as marked by EEA1
(Supplementary Material, Fig. S3) (29). When BBS1
protein was depleted by shRNA-mediated RNA interference
1326 Human Molecular Genetics, 2009, Vol. 18, No. 7(Supplementary Material, Fig. S4), LepRb was found in abnor-
mally large vesicles near the nucleus (approximately 7% of the
transfected cells; Fig. 6). We found similar mistrafﬁcking of
LepRb when BBS2 protein was depleted (Fig. 6), indicating
that the requirement of BBS proteins for LepRb trafﬁcking
is not limited to BBS1. These data suggest that BBS proteins
are required for proper trafﬁcking of the LepRb most likely
between the Golgi and the ciliary and/or plasma membrane.
DISCUSSION
BBS proteins have been implicated in protein/vesicle trafﬁck-
ing along the microtubule (9,10). However, how this general
function is associated with individual components of the
BBS phenotype was unknown. The present study provides
the pathophysiological mechanism of obesity in BBS at the
molecular level. Our study provides evidence that leptin resist-
ance resulting from aberrant LepR trafﬁcking and attenuated
LepR signaling in the hypothalamus is a cause of obesity
associated with BBS. We demonstrate that eliminating
obesity and hyperleptinemia does not restore leptin sensitivity
in BBS mice, indicating that leptin resistance is intrinsic rather
than secondary to hyperleptinemia and obesity. We also
demonstrate that the BBS1 protein physically interacts with
the signaling isoform of LepR, LepRb and that BBS proteins
are required for proper trafﬁcking of the LepRb.
Figure 4. Defective POMC neurons in Bardet-Biedl syndrome (BBS) mice. (A) Hypothalamic levels of agouti-related protein (AgRP), neuropeptide Y (NPY)
and proopiomelanocortin (POMC) mRNA in normally fed Bbs2, Bbs4 and Bbs6 null mice when compared with wild-type controls (n ¼ 6–9). (B) Effect of 48 h
fasting (relative to the normally fed state) on hypothalamic AgRP, NPY and POMC mRNA levels in wild-type, Bbs2 and Bbs4 null mice (n ¼ 4–5). (C) Immu-
nohistochemical staining of POMC-positive neurons. Coronal sections of the wild-type, Bbs2
2/2 (2KO) and Bbs6
2/2 (6KO) brains were stained with anti-
POMC antibodies and representative sections are shown. (D) Average number of POMC-positive neurons in the arcuate nucleus. POMC-positive cells in
ﬁve sections within the similar position from each animal were counted and average number of POMC neurons per hemisphere is shown (n ¼ 3–4). Data
are mean+SEM.  P , 0.05 compared with wild-type mice.
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ing between the Golgi and speciﬁc areas of the plasma
membrane (e.g. lipid raft, ciliary membrane). In the absence
of BBS proteins, LepRb trafﬁcking was perturbed and
LepRb signaling was attenuated. This is consistent with the
previous ﬁndings that the BBS proteins are necessary for the
localization of G protein-coupled receptors (GPCRs) to neuro-
nal cilia (30). Although we tested several antibodies against
LepR, we were not able to detect LepRb in the mouse brain
slices. This may be owing to the low level of surface
expression and fast turnover of the LepRb (26,27). However,
LepRb has been found in the cilium of the olfactory epithelial
cells (31), suggesting that LepRb may localize to the cilium of
hypothalamic neurons.
Of the BBSome subunits, only BBS1 showed physical inter-
action with LepRb. We previously demonstrated that BBS1
also interacted with Rabin8, a GDP/GTP exchange factor for
Rab8 (9). These observations raise the possibility that BBS1
is the cargo-binding subunit of the BBSome. Thus, it is of
interest to test whether the GPCRs mislocalized in BBS
mutant neurons (e.g. Sstr3 and Mchr1) also interact with
BBS1 (30). However, similar LepRb trafﬁcking defects
observed in BBS2 depleted cells and no obvious genotype–
phenotype correlation among various BBS mutations indicate
that integrity of the BBSome is important for its function in
trafﬁcking and that loss of any BBSome subunits could lead
to the same phenotype (mistrafﬁcking of the cargo).
Interestingly, in BBS animals loss of LepRb function
appears to be selective. Indeed, although expression of Agrp,
Npy and Pomc are all regulated by leptin (1), only Pomc
gene expression was affected in BBS mice. Thus, the loss of
leptin action appears to be restricted to the POMC neurons.
Genetic ablation of LepRb speciﬁcally in POMC neurons
leads to hyperphagia and increased fat mass in mice (32,33).
In BBS mice, attenuated LepRb signaling in POMC neurons
is likely the main cause of obesity. These results are consistent
with the recent ﬁndings by Davenport et al. (34) showing that
disruption of intraﬂagellar transport proteins, Tg737 or Kif3a,
which are required for ciliogenesis, speciﬁcally in POMC
neurons resulted in hyperphagia and obesity in mice. In
addition, while BBS mice are resistant to leptin’s action to
decrease body weight and food intake, they have a preserved
sympathetic/cardiovascular response to leptin (11), supporting
the selective loss of LepRb function in BBS mice. In fact,
leptin signaling is not completely abolished in BBS mice. A
fraction of the LepRb signaling is present as shown by residual
STAT3 activation following leptin treatment. Thus, BBS pro-
teins appear to be required for ‘efﬁcient’ LepRb signaling,
which is necessary to control feeding behavior, while ‘low’
level of LepRb signaling is still transduced in the absence of
BBS proteins and this level of signaling is sufﬁcient to
increase sympathetic nerve activity and blood pressure. Local-
ization of the LepRb to a speciﬁc domain in the plasma mem-
brane may be required for this ‘efﬁcient’ signaling, while
LepRb elsewhere in the plasma membrane may be sufﬁcient
to transduce the ‘low’ level of signal. Alternatively, the
requirement for BBS proteins in the LepRb signaling may
be speciﬁc to certain cell types and/or downstream effectors.
These are interesting questions that warrant further studies.
In humans, variants of BBS2, BBS4 and BBS6 genes have
been reported to be associated with obesity in non-BBS indi-
viduals (35). Indeed, a variant in the BBS2 gene was related
to common adult obesity, and polymorphisms in BBS4 and
BBS6 genes were associated with common early-onset child-
hood obesity and common morbid adult obesity. Whether
the speciﬁc variants of the BBS genes associated with
common obesity affect LepRb signaling and/or trafﬁcking
remains to be determined.
Figure 5. Bardet-Biedl syndrome (BBS) proteins mediate LepRb trafﬁcking. (A) Interaction of BBS1 with the LepRb. HA-tagged BBS proteins (BBS1–5 and
7–9) were transiently transfected with FLAG-tagged LepRb and interactions were examined by co-immunoprecipitation assays. Expression levels of each BBS
protein and LepRb in the lysates were shown in the bottom and middle panels, respectively. Co-immunoprecipitated LepRb was shown in the top panel. IP,
immunoprecipitation; IB, immunoblotting. (B) The signaling isoform of LepR, LepRb, but not the short isoform LepRa, interacts with BBS1. (C) C-terminal
cytoplasmic domain of LepRb (LepRb cyto) is sufﬁcient to interact with BBS1. Myc-GFP was used as a negative control. (D) BBS1 M390R mutation disrupts
the BBS1–LepRb interaction. Others are the same as in (A).
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accounts for obesity in mouse models of BBS. Our ﬁndings
indicate that mistrafﬁcking and attenuated signaling of the
LepRb is the main cause of energy imbalance leading to
obesity in BBS. This defect represents a novel pathophysiolo-
gical mechanism of leptin resistance with potential implication
for common human obesity.
MATERIALS AND METHODS
For a detailed description of the Materials and Methods, please
see Supplementary Material, which is published as supporting
information on the Human Molecular Genetics website.
Animals
Generation of Bbs2
2/2, Bbs4
2/2 and Bbs6
2/2 mice and gen-
otyping was described previously (15–17). The University of
Iowa Animal Research Committee approved all protocols.
Leptin normalization/leptin resistance study
Sex- and age-matched controls and BBS mice were housed in
individual cages at 6–8 weeks of age. Bbs2
2/2, Bbs4
2/2 and
Bbs6
2/2 animals were given 70–80% of food consumed by
wild-type controls everyday until the day before leptin treat-
ment. Animals were equipped with ICV cannulae as pre-
viously described (36). Vehicle or recombinant mouse leptin
(2 mgi n1ml, R&D Systems, Minneapolis, MN) was injected
ICV. Mice were sacriﬁced 24 h after ICV leptin adminis-
tration, and food intake and body weight were measured.
For STAT3 phosphorylation analysis, food was removed
18 h before ICV injection. Leptin or vehicle was injected
ICV and animals sacriﬁced 2 h later by CO2 asphyxiation.
Hypothalami were quickly dissected and homogenized in the
lysis buffer. Protein extracts were loaded onto 4–12%
NuPAGE Bis–Tris gels and analyzed by immunoblotting.
MTII study
Sex- and age-matched wild-type controls and Bbs2
2/2 and
Bbs6
2/2 animals were housed in individual cages at 9–13
weeks of age with free access to food and water. Two weeks
later, mice were implanted with ICV cannulae as described
above. Body weight and food intake were measured daily
for four consecutive days before ICV injection and used as
baseline values. For each genotype, the mice treated with
vehicle or MTII were weight-matched. Animals were sacri-
ﬁced 24 h after MTII (1 mgi n1ml; Phoenix Pharmaceuticals
Inc., Burlingame, CA) or vehicle injection by CO2 asphyxia-
tion, and body weight, food consumption and the weights of
brown adipose tissue and reproductive fat were measured as
described previously (11,25,36).
RNA extraction and quantitative reverse
transcriptase-polymerase chain reaction
RNA was extracted from mouse hypothalami using TRIzol
Reagent (Invitrogen, Carlsbad, CA). Complementary DNA
was synthesized from 1 mg of total RNA and used for qPCR
with iQ SYBR Green Supermix (Bio-Rad, Hercules, CA)
and Mx3000P QPCR System (Stratagene, La Jolla, CA). Rela-
tive gene expression was calculated by the DDCt method fol-
lowing normalization with RPL19 (37). The PCR products
were conﬁrmed by the melt-curve analysis and sequencing.
Primer sequences are shown in Supplementary Material text.
Immunohistochemistry
Mice were perfused with 4% paraformaldehyde/0.5% glutaral-
dehyde in phosphate-buffered saline (2.5 ml/min; 50 ml).
Entire brain was excised and incubated in the same ﬁxative
overnight at 48C then transferred to 30% sucrose solution.
Brains were vibratome-sectioned with 45 mm thickness.
Figure 6. Bardet-Biedl syndrome (BBS) proteins are required for LepRb traf-
ﬁcking. (A) Alteration of the LepRb trafﬁcking in BBS1- and BBS2-depleted
cells. ARPE-19 cells were transfected with FLAG–LepRb together with
scrambled (control), BBS1 or BBS2 RNAi constructs. Localization of
LepRb (green) and TGN46 (red) was probed by indirect immunoﬂuorescence
microscopy. Merged images with DAPI staining (blue; nuclei) are shown.
(Scale bars: 10 mm). (B) Percentage of transfected cells (determined by
FLAG immunoﬂuorescence) with large vesicles. Values are average of three
experiments and a minimum of 120 cells was counted in each experiment.
Data are mean+SEM.
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buffered saline with 0.25% Triton X-100 (0.25% Triton
X-100), blocked by 3% normal goat serum and decorated
with rabbit anti-POMC antibody (1:4000), biotinylated goat
anti-rabbit IgG (1:200) and Vectastain Elite ABC kit (Vector
Laboratories, Burlingame, CA).
Transfection and co-immunoprecipitation
HEK293T cells were transfected in six-well plates with 1 mg
of CS2FLAG-LepR and 1 mg of indicated HA-tagged BBS
proteins using FuGENE HD (Roche Applied Science, Indiana-
polis, IN). Cell lysates were immunoprecipitated with anti-Myc
(9E10; SantaCruz, Santa Cruz, CA) or anti-HA (F-7;
SantaCruz, Santa Cruz, CA) antibodies conjugated to agarose.
Precipitated proteins were analyzed by standard sodium
dodecyl sulfate–polyacrylamide gel electrophoresis and immu-
noblotting.
Immunoﬂuorescence
ARPE-19 cells were seeded on glass cover slips in 24-well
plates and transfected with total 1 mg of DNA using
FuGENE HD (Roche, Indianapolis, IN). Cells were ﬁxed
with methanol for 6 min at 2208C, blocked with 5% BSA
and 3% normal goat serum and decorated with indicated
primary antibodies. Alexa Flour 488 goat anti-mouse IgG
(Invitrogen, Carlsbad, CA) and Alexa Flour 568 goat
anti-rabbit IgG (Invitrogen, Carlsbad, CA) were used to
detect primary antibodies.
Statistical analysis
Results were expressed as mean+SEM. Comparisons
between groups were made by one-way or two-way analysis
of variance (ANOVA) with Fisher LSD method post-test
analysis for pairwise multiple comparisons, as appropriate.
P , 0.05 was considered to be statistically signiﬁcant.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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